全球心臟再同步治療設備市場：市場規模、佔有率和趨勢分析（2025-2032 年）

全球心臟再同步治療設備市場報告

2025年全球心臟再同步治療設備市場規模為29.8億美元。在預測期內，該市場預計將以0.7%的複合年成長率成長，到2032年將達到約31億美元。

本報告對全球心臟再同步治療（CRT）設備市場進行了分析，涵蓋心臟再同步治療心律調節器和心臟再同步治療去心房顫動。報告結構旨在反映全球CRT市場及其具體的臨床、競爭和報銷趨勢，內容順序與附件範例文件一致。

本報告詳細分析了銷售量、平均售價、手術例數、市場規模和成長趨勢，包括截至2022年的歷史數據和截至2032年的市場預測。報告中還涵蓋了市場促進因素和限制因素、近期併購、公司概況、產品系列和主要競爭對手。因此，本報告為心臟節律管理領域這一高度專業且具有重要臨床意義的細分市場提供了具有策略意義的觀點。

此類別的成長較為穩定而非迅猛。隨著全球人口老化，越來越多的心臟衰竭患者符合器械治療的條件，預計器械數量將逐步增加。在市場中，CRT-D系統仍佔著尤為重要的地位。這是因為許多醫師在病患經濟條件允許且認為有必要獲得額外臨床風險保障時，更傾向於選擇具備去心房顫動功能的器械。此外，隨著醫療保健可近性的提高，預計低收入國家在長期內也將存在一定的成長潛力，但這仍與健保報銷政策和當地器械價格的可負擔性密切相關。

總體而言，全球心臟再同步治療（CRT）市場是一個穩定且具有臨床永續的領域，這得益於心臟衰竭的日益嚴重、人口老齡化以及器械療法在減少長期醫療需求方面的持續價值。儘管其成長速度不如快速成長的電生理（EP）和無導線心律調節器領域，但它仍然是全球心臟器械產業的重要支柱。

市場概覽

全球心臟再同步治療（CRT）設備市場包括用於治療伴隨室性心律不整的心臟衰竭患者的植入式系統。這些設備透過調節心室間期收縮來提高心臟效率，緩解症狀，並幫助改善特定患者的長期臨床療效。此市場包括僅提供心律調節器功能的CRT-P系統和去心房顫動功能結合的CRT-D系統。

心臟節律治療（CRT）在更廣泛的心臟節律管理領域中扮演著獨特的角色。與標準心律調節器不同，CRT系統用於臨床病情較為複雜的患者，這些患者通常患有嚴重的心臟衰竭或結構性心臟疾病。這意味著，CRT治療的重點在於改善心臟功能、降低住院率和控制長期併發症，而不僅僅是提供節律支持。因此，儘管成長速度有所放緩，CRT仍然是植入式心臟裝置中最具臨床影響力的領域之一。

市場中的關鍵內部因素之一是CRT-P和CRT-D之間的關係。在許多醫療機構中，醫生傾向於選擇CRT-D，因為它能為高風險患者提供額外的保護，並預防危及生命的心室心律不整。在經濟可行且臨床合理的情況下，這種趨勢推動了CRT-D在高附加價值市場領域的應用。同時，醫療保險政策、國家治療指南和醫院預算壓力也會影響CRT-D相對於CRT-P的選擇頻率。

此外，市場也受到技術成熟度的影響。 CRT如今已成為一種成熟的治療手段，被醫生廣泛認可，且競爭格局相對集中。這種成熟度雖然支撐了穩定的需求，但也限制了已開發地區透過新用戶成長實現成長的潛力。因此，CRT的成長更依賴人口成長、臨床設備更新換代、設備更新周期以及新興醫療體系的選擇性成長，而非治療族群的急劇擴張。

市場促進因素

使用CRT設備降低手術和長期照護成本。

全球心臟再同步治療（CRT）市場的主要驅動力之一是其能夠減輕心臟衰竭患者的長期治療負擔。心血管疾病仍是全球首要死因，每年導致超過2,000萬人死亡。光是在歐洲，每年約有390萬人死於心血管疾病，約佔所有死亡人數的40%。這給醫療保健系統帶來了沉重的負擔，包括反覆住院、心臟衰竭惡化以及高昂的長期照護費用。

心臟再同步治療（CRT）設備因其有助於提高患者病情穩定性並降低再入院率而持續獲得支持。對於療效良好的患者，該治療方法可以減少後續醫療需求並提高生活品質。這使得CRT不僅在患者照護方面具有價值，而且在健康經濟學方面也具有重要意義。儘管初始植入成本仍然較高，但醫院和保險公司仍然認可其價值，這為該領域的發展提供了支持。

CRT-D系統拯救生命的潛力

CRT-D 的救命潛力仍是推動市場發展的關鍵因素。大規模臨床試驗，特別是 MADIT CRT 系列試驗，顯示 CRT-D 系統能夠成功終止超過 98% 的危及生命的心室心律不整事件。這種保護程度與院外心臟麻痹後通常低於 10% 的低存活率形成鮮明對比。

這種顯著的生存優勢是醫生繼續支持合格的患者選擇CRT-D的依據。雖然CRT-D系統比CRT-P設備更昂貴，但其提供的額外保護功能使其成為極具吸引力的選擇，前提是患者的經濟負擔和保險報銷可以接受。這也是CRT-D在整個CRT市場中持續佔重要地位的主要原因之一。

人口老化和心臟衰竭負擔日益加重

人口結構變化也為市場帶來益處。隨著人口老化，心臟衰竭、傳導異常和結構性心臟疾病患者的數量持續增加。這擴大了心臟再同步治療（CRT）的適用人群。該領域已趨於成熟，人口結構變化帶來的壓力將持續支撐全球大多數市場對此手術的需求。

這一趨勢尤其重要，因為CRT的適應症患者群體往往與老年人和患有累積性心血管疾病的人重疊。即使每年合格的患者數量略有增加，尤其是在穩定的替代需求和持續的心臟衰竭率的共同作用下，也能在長期內維持市場穩定。

市場限制

設備和導線召回

CRT市場面臨的最大阻礙因素之一是設備和導線召回的影響。在植入式心臟治療領域，召回事件會對醫生的信心、醫院的採購行為以及公司的盈利產生直接而強烈的衝擊。當競爭對手面臨可靠性問題時，其他供應商往往會採取更積極的措施來贏回因此而流失的客戶。

這一趨勢在CRT領域尤其重要，因為該手術費用昂貴，且患者的病情複雜。因此，可靠性問題可能會對採購決策產生長達數季甚至更長的影響。即使整體市場需求穩定，召回事件也可能造成短期供應中斷，並加劇監管機構對整個產業的審查。

CRT置入手術高成本

第二個主要阻礙因素是CRT植入手術的總費用高昂。 CRT手術仍然是最昂貴的心臟器械介入治療之一，而且近年來總植入費用並未大幅下降。這影響到CRT-P和CRT-D，但自然會為去心房顫動領域帶來更大的經濟負擔。

由於這項手術對醫院和病人而言仍然費用高昂，成本效益問題持續限制其推廣應用。在保險覆蓋不足或醫院預算控制嚴格的地區，這個問題尤其突出。因此，儘管該治療方法具有明顯的臨床價值，但其應用成長仍受到阻礙。

市場成熟度

另一個阻礙因素是該領域本身的成熟度。 CRT 已在許多先進的醫療系統中得到應用，治療指南也已成熟。這意味著成長並非源自於首次接受治療的合格患者數量的急劇增加，而是受人口結構變化、置換手術以及在低滲透率地區的選擇性擴張所驅動。雖然這種趨勢有助於市場穩定，但也限制了整體成長率。

市場保險覆蓋範圍和數據範圍

定量範圍

市場規模、市佔率、市場預測、市場成長率、銷售量、平均售價。

定性範圍

市場促進因素和限制因素、成長趨勢、近期併購、公司概況、產品系列和主要競爭對手。

目標期

基準年：2025 年，歷史資料截至 2022 年，預測至 2032 年。

包含的資料類型

銷售量、平均售價、治療次數、市場規模和成長趨勢。

本報告旨在透過對 CRT 市場規模的詳細分析，以及對受臨床需求、價格壓力和報銷方案驅動的採用情況的實際分析，為策略規劃、競爭基準分析和產品定位提供支援。

目標市場及區隔

• 本報告涵蓋全球心臟再同步治療設備市場，並進一步細分為以下幾個部分：

CRT-P市場

這部分包括心臟衰竭患者的心臟再同步治療心律調節器，這些患者不需要去心房顫動支持，但需要心室再同步治療。

CRT-D市場

這部分包括心臟再同步治療去心房顫動，它將再同步治療與植入式去心房顫動功能結合。

每個細分市場均根據銷售量、平均售價和市場總值進行分析，並包括截至 2032 年的預測和截至 2022 年的歷史數據。這種細分反映了 CRT 市場的核心決策框架，其中治療方法選擇通常取決於心臟衰竭需求和心律不整風險狀況。

競爭分析

美敦力在CRT市場（包括CRT-D和CRT-P兩大領域）持續維持全球領先地位。其現有產品系列包括Cobalt、Crome、Percepta、Serena和Solara。這些系統具備自適應CRT演算法、心臟衰竭診斷功能以及長期耐用性，持續鞏固了美敦力在植入手術領域的領先地位。憑藉其豐富的產品組合、醫生認可度和卓越的業績記錄，美敦力預計將在2025年之前保持主導地位。

波士頓科學公司是第二大競爭對手，其CRT產品組合已全面升級，遠超過以往的舊系統。在CRT-D領域，該公司與RESONATE和VIGILANT等平台競爭，這些平台強調更長的電池壽命和更先進的心臟衰竭診斷功能。在CRT-P領域，波士頓科學公司憑藉VALITUDE和INGENIO系列產品保持領先地位，這些產品擁有廣泛的MRI相容認證和可靠的起搏性能。這項升級後的產品陣容使該公司在大規模心臟衰竭項目中保持了穩固的市場佔有率。

雅培在全球心臟復甦（CRT）系統市場佔有第三大佔有率，這得益於其Entrant、Gallant、Quadra Allure MP系統以及其他升級版CRT-D和CRT-P平台。雅培專注於多點起搏、先進的心臟衰竭管理功能和強大的遠端監測。憑藉著始終如一的可靠性和不斷提升的性能，該公司在全球市場保持著強勁的競爭優勢，直至2025年。

總體而言，競爭格局由與醫生的長期關係、發生器的耐用性、心臟衰竭診斷和遠端監測方面的優勢以及支持去心房顫動的能力所決定。

科技和醫療治療的發展趨勢

CRT市場最顯著的趨勢之一是，只要病患病情允許且成本效益高，CRT-D仍是首選。醫生通常傾向於選擇具有去心房顫動功能的CRT-D，因為它能為高風險心臟衰竭患者提供額外的保護。

另一個重要趨勢是心臟衰竭診斷能力和遠端監測的價值日益提升。現代心臟再同步治療（CRT）系統的功能已超越了單純的起搏；它們透過資料收集、事件警報和更有效率的追蹤流程，幫助臨床醫生管理慢性心臟衰竭。

電池壽命仍然是一項至關重要的產品發展趨勢。延長電池使用壽命可以改善長期經濟效益，並減輕臨床病情複雜的患者群體更換電池的負擔。

最後，MRI相容顯示器和平台的不斷改進持續提升著該領域產品的標準化水準。雖然這些改進並未從根本上改變治療本身，但它們提升了設備的價值，並有助於在成熟的市場中保持臨床信心。

地區

本報告涵蓋全球調查區域，包括北美、歐洲、亞太地區、拉丁美洲以及中東和非洲。

一份長達 108 頁的詳細市場分析、市場區隔和預測數據。

調查方法附錄和簡稱詞彙表。

這份報告的意義

到 2032 年，全球 CRT 市場中最穩定的商業機會在哪裡？

您可預期未來全球市場上CRT-P和CRT-D之間的比例會發生怎樣的變化？

心臟衰竭的負擔、人口老化和報銷政策在塑造需求方面發揮著怎樣的作用？

醫療設備召回和高昂的治療費用如何影響競爭和市場滲透率？

在 CRT-P 和 CRT-D 領域，哪些公司已經確立了最強的地位，它們的統治地位能在多大程度上持續下去？

在成熟但臨床意義重大的心臟衰竭治療設備領域，供應商、投資者和策略團隊該如何評估商機？

iData Research 的「全球心臟再同步治療設備市場報告」透過詳盡的市場規模、價格分析、市場細分和競爭格局信息，解答了這些問題。在心臟節律管理這個具有重要策略意義的領域，您可以利用這份報告與競爭對手進行比較，了解治療需求，並輔助制定策略。

目錄

圖表清單

調查方法

• 步驟 1：計劃啟動與團隊組建
• 步驟 2：準備資料系統並進行二次調查。
• 步驟 3：設計和準備訪談和調查問卷。
• 步驟 4：進行初步調查
• 步驟 5：調查與分析：建立基準估計值
• 步驟 6：市場預測與分析
• 步驟 7：辨識策略機遇
• 步驟 8：最終審核和市場推廣
• 步驟 9：客戶回饋與市場監測

全球關稅的影響

心臟再同步治療設備市場

• 全球心臟再同步治療設備市場概覽
• 競爭分析
• 目標程式
• 目標市場
• 目標區域

介紹

• 心臟再同步治療心律調節器（CRT-PS）
• 心臟再同步治療去心房顫動（CRT-D）

手術次數

• 總體CT置入流程
• 初始植入CRT程序
• 更換CRT手術

市場概覽

• 按細分市場
• 按地區

市場分析與預測

• 整體CRT設備市場
• Crt-P市場
• Crt-D市場

促進因素和抑制因素

競爭性市佔率分析

簡稱

Global Cardiac Resynchronization Therapy Device Market Report

The global cardiac resynchronization therapy device market was valued at $2.98 billion in 2025. Over the forecast period, the market is expected to grow at a CAGR of 0.7% to reach approximately $3.1 billion by 2032.

The full report suite on the global market for cardiac resynchronization therapy, or CRT, devices includes cardiac resynchronization therapy-pacemakers and cardiac resynchronization therapy-defibrillators. This report follows the same structure and content order shown in the attached example document, adapted to the global CRT market and its specific clinical, competitive and reimbursement dynamics .

This report provides detailed analysis of unit sales, average selling prices, procedure numbers, market size and growth trends, with historical data to 2022 and market forecasts through 2032. It also includes market drivers and limiters, recent mergers and acquisitions, company profiles, product portfolios and leading competitors. The result is a focused strategic view of a highly specialized but clinically important segment within cardiac rhythm management.

Growth in the category is steady rather than rapid. The number of devices is expected to rise gradually as the global population ages and more patients become candidates for heart failure device therapy. Within the market, CRT-D systems continue to hold particular importance because many physicians prefer to include defibrillation capacity when the patient can afford it and when clinical risk supports the added protection. Growth potential is also somewhat stronger in lower-income countries over the long term as healthcare access improves, though this remains closely tied to reimbursement policy and local device affordability.

Overall, the global CRT market is a stable, clinically durable category supported by heart failure burden, aging populations and the continued value of device-based therapy in reducing long-term healthcare utilization. While it does not show the same growth rate as faster-moving EP or leadless pacing segments, it remains an important pillar of the global cardiac device industry.

Market Overview

The global cardiac resynchronization therapy device market includes implantable systems designed to treat heart failure patients with ventricular dyssynchrony. These devices coordinate contraction between the ventricles to improve cardiac efficiency, reduce symptoms and support better long-term clinical outcomes in appropriately selected patients. The market includes both CRT-P systems, which provide pacing only, and CRT-D systems, which combine resynchronization therapy with defibrillation capability.

CRT occupies a distinct role within the broader cardiac rhythm management landscape. Unlike standard pacemakers, CRT systems are used in more clinically complex patients who often have significant heart failure burden and structural disease. This means the therapy is less about simple rhythm support and more about improving cardiac performance, reducing hospitalization and managing long-term morbidity. Because of this, CRT remains one of the more clinically impactful segments in implantable cardiac devices, even though its growth rate is modest.

A major internal dynamic within the market is the relationship between CRT-P and CRT-D. In many settings, physicians prefer CRT-D because it adds protection against life-threatening ventricular arrhythmias in patients already at high risk. When financially feasible and clinically justified, this pushes utilization toward the higher-value segment of the market. At the same time, reimbursement policy, national treatment pathways and hospital budget pressure can influence how frequently CRT-D is selected over CRT-P.

The market is also influenced by the maturity of the technology. CRT is now a well-established therapy category with broad physician familiarity and a relatively concentrated competitive landscape. That maturity supports steady demand but also limits upside from first-time adoption in developed regions. As a result, growth depends more on demographic expansion, clinical replacement need, device refresh cycles and selective growth in emerging healthcare systems than on dramatic broadening of the treatment base.

Market Drivers

Use of CRT Devices to Reduce Surgical and Long-Term Care Cost

One of the main drivers of the global CRT market is the therapy's ability to reduce long-term treatment burden in heart failure patients. Cardiovascular disease remains the leading cause of death worldwide, responsible for more than 20 million deaths annually. In Europe alone, cardiovascular disease accounts for about 3.9 million deaths each year, representing roughly 40% of all deaths. This places enormous pressure on health systems through repeat hospital admissions, worsening heart failure and high long-term care costs.

CRT devices continue to gain support because they help improve patient stability and reduce readmission rates. In patients who respond well, the therapy can lessen downstream healthcare utilization and improve quality of life. This makes CRT valuable not only from a patient care perspective but also from a health economics perspective. Hospitals and payers continue to recognize this value, which supports the category even when upfront implant costs remain high.

Lifesaving Potential of CRT-D Systems

The lifesaving potential of CRT-D remains another major market driver. Large clinical trials, especially the MADIT CRT series, have shown that CRT-D systems can successfully terminate life-threatening ventricular arrhythmias in more than 98% of events. That level of protection stands in sharp contrast to the poor survival typically seen after out-of-hospital sudden cardiac arrest, where real-world survival often remains below 10%.

This strong survival advantage continues to support physician preference for CRT-D in eligible patients. Even though CRT-D systems cost more than CRT-P devices, the additional protection they provide makes them highly attractive where patient affordability and reimbursement allow. This is one of the main reasons CRT-D continues to hold such an important position within the overall CRT market.

Aging Population and Expanding Heart Failure Burden

The market also benefits from demographic change. As populations age, the number of patients with heart failure, conduction abnormalities and structural heart disease continues to rise. This expands the pool of patients who may be evaluated for CRT. Although the category is mature, demographic pressure continues to support procedure demand in most global markets.

This trend is especially important because CRT candidacy often overlaps with older age and accumulated cardiovascular burden. Even modest annual increases in eligible patients can sustain the market over time, particularly when combined with stable replacement demand and ongoing heart failure incidence.

Market Limiters

Recall of Device and or Leads

One of the largest limiters in the CRT market is the effect of device or lead recalls. In implantable cardiac therapy, recalls can have a strong and immediate effect on physician trust, hospital purchasing behavior and company profitability. Once a competitor suffers a reliability event, other suppliers often move aggressively to capture displaced accounts.

This dynamic matters especially in CRT because the procedures are high value and the patients are medically complex. Reliability concerns can therefore influence procurement decisions for multiple quarters or longer. Even if the total market need remains stable, recalls can create short-term disruption and increase regulatory attention across the category.

High Cost of CRT Implantation Procedures

A second major limiter is the high overall cost of CRT implantation. CRT procedures remain among the more expensive cardiac device interventions, and total implant cost has not meaningfully decreased in recent years. This affects both CRT-P and CRT-D, although the financial burden is naturally greater in the defibrillator segment.

Because the procedures remain expensive for hospitals and patients, affordability continues to limit how many can be performed. This is particularly important in regions where reimbursement is incomplete or where hospitals face tighter budget controls. As a result, unit growth stays constrained even though the therapy has clear clinical value.

Market Maturity

Another limiter is the maturity of the category itself. CRT is already well established in many developed healthcare systems, and the therapy guidelines are mature. This means growth is not being driven by a dramatic new expansion in the number of eligible patients receiving first-time therapy. Instead, it is driven more by demographics, replacement procedures and selective expansion in less penetrated regions. That dynamic supports stability, but it also limits overall growth rate.

Market Coverage and Data Scope

Quantitative Coverage

Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.

Qualitative Coverage

Market drivers and limiters, growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.

Time Frame

Base year 2025, historical data to 2022 and forecasts through 2032.

Data Types Included

Unit sales, average selling prices, procedure numbers, market size and growth trends.

This report is designed to support strategic planning, competitive benchmarking and product positioning by combining detailed CRT market sizing with practical analysis of clinical demand, pricing pressure and reimbursement-driven adoption.

Markets Covered and Segmentation

• The report covers the Global Cardiac Resynchronization Therapy Device Market, further segmented into:

CRT-P Market

This segment includes cardiac resynchronization therapy-pacemakers used in heart failure patients requiring ventricular resynchronization without defibrillation support.

CRT-D Market

This segment includes cardiac resynchronization therapy-defibrillators that combine resynchronization therapy with implantable defibrillation capability.

Each segment is analyzed by unit sales, average selling prices and total market value, with forecasts through 2032 and historical data to 2022. This segmentation reflects the core decision framework within the CRT market, where therapy selection often depends on both heart failure needs and arrhythmic risk profile.

Competitive Analysis

Medtronic remains the global leader in the CRT market across both CRT-D and CRT-P segments. Its current portfolio includes Cobalt, Crome, Percepta, Serena and Solara. These systems incorporate adaptive CRT algorithms, heart failure diagnostics and long-term device longevity that continue to support the company's leadership across major implanting centers. Medtronic's combination of broad portfolio depth, physician familiarity and installed base presence gives it a durable leading position through 2025.

Boston Scientific is the second-largest competitor and has modernized its CRT portfolio well beyond older legacy systems. In CRT-D, the company competes with platforms such as RESONATE and VIGILANT, which emphasize extended battery longevity and advanced heart failure diagnostics. In CRT-P, Boston Scientific continues to support its position through the VALITUDE and INGENIO families, which provide broad MRI conditional labeling and dependable pacing performance. This refreshed lineup helps the company maintain a stable share position across large heart failure programs.

Abbott holds the third-largest global CRT share, supported by systems such as Entrant, Gallant and Quadra Allure MP, alongside other updated CRT-D and CRT-P platforms. Abbott emphasizes multipoint pacing, advanced heart failure management functions and strong remote monitoring capabilities. Consistent reliability and refreshed performance characteristics have helped the company remain a strong competitor in the global market through 2025.

Overall, the competitive landscape is shaped by long-standing physician relationships, generator longevity, heart failure diagnostics, remote monitoring strength and the ability to support both pacing-only and defibrillation-inclusive CRT therapy.

Technology and Practice Trends

One of the most important trends in the CRT market is the continued preference for CRT-D where patient condition and affordability support it. Physicians often favor the addition of defibrillation because of the extra protection it provides in high-risk heart failure populations.

Another important trend is the increasing value of heart failure diagnostics and remote monitoring. Modern CRT systems do more than pace. They help clinicians manage chronic heart failure through data collection, event alerts and more efficient follow-up workflows.

Battery longevity remains a key product trend as well. Longer service life supports better long-term economics and reduces replacement burden in a patient group that is already clinically complex.

Finally, MRI conditional labeling and platform refinement continue to standardize expectations across the category. These improvements do not radically change the therapy itself, but they strengthen device value and help preserve clinical confidence in a mature market.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

108 pages of detailed market analysis, segmentation and forecast data.

Methodology Appendix and Acronym Glossary.

Why This Report

Where are the most stable opportunities in the global CRT market through 2032?

How is the balance between CRT-P and CRT-D expected to evolve across global markets?

What role do heart failure burden, aging populations and reimbursement policy play in shaping unit demand?

How do device recalls and high procedure costs affect competition and adoption?

Which companies hold the strongest positions in CRT-P and CRT-D, and how durable are those advantages?

How can suppliers, investors and strategy teams assess opportunity in a mature but clinically critical heart failure device category?

The Global Cardiac Resynchronization Therapy Device Market Report from iData Research answers these questions with detailed market sizing, pricing analysis, segmentation and competitive intelligence. Use it to benchmark competitors, understand therapy demand and support strategy in a stable but strategically important segment of cardiac rhythm management.

TABLE OF CONTENT

List Of Figures

List Of Charts

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Cardiac Resynchronization Therapy Device Market

• 6.1.1 Global Cardiac Resynchronization Therapy Device Market Overview
• 6.1.2 Competitive Analysis
• 6.1.3 Procedures Included
• 6.1.4 Markets Included
• 6.1.5 Regions Included

Introduction

• 6.1.6 Cardiac Resynchronization Therapy-Pacemakers (Crt-Ps)
• 6.1.7 Cardiac Resynchronization Therapy-Defibrillators (Crt-Ds)

Procedure Numbers

• 6.1.8 Total Crt Placement Procedures
• 6.1.9 Initial Placement Crt Procedures
• 6.1.10 Replacement Crt Procedures

Market Overview

• 6.1.11 By Segment
• 6.1.12 By Region

Market Analysis And Forecast

• 6.1.13 Total Crt Device Market
• 6.1.14 Crt-P Market
  • 6.1.14.1 Initial Placement Crt-P Market
  • 6.1.14.2 Replacement Crt-P Market
• 6.1.15 Crt-D Market
  • 6.1.15.1 Initial Placement Crt-D Market
  • 6.1.15.2 Replacement Crt-D Market

Drivers And Limiters

• 6.1.16 Market Drivers
• 6.1.17 Market Limiters

Competitive Market Share Analysis

Abbreviations

LIST OF CHARTS

• Chart 6-1: CRT Device Market, Global, 2022 - 2032
• Chart 6-2: CRT Device Placement Procedures, Global, 2025
• Chart 6-3: CRT Placement Procedures by Segment, Global, 2022 - 2032
• Chart 6-4: CRT Device Market by Segment, Global, 2022 - 2032
• Chart 6-5: CRT Device Market by Region, Global, 2022 - 2032
• Chart 6-6: Leading Competitors, CRT Market, Global, 2025

LIST OF FIGURES

• Figure 6-1: CRT Device Procedures Covered
• Figure 6-2: CRT Device Markets Covered
• Figure 6-3: CRT Device Regions Covered, Global (1 of 2)
• Figure 6-4: CRT Device Regions Covered, Global (2 of 2)
• Figure 6-5: CRT Placement Procedures by Segment, Global, 2022 - 2032
• Figure 6-6: CRT Placement Procedures by Region, Global, 2022 - 2032
• Figure 6-7: CRT Placement Procedures by Country, North America, 2022 - 2032
• Figure 6-8: CRT Placement Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 6-9: CRT Placement Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 6-10: CRT Placement Procedures by Country, Western Europe, 2022 - 2032
• Figure 6-11: CRT Placement Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 6-12: CRT Placement Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 6-13: CRT Placement Procedures by Country, Middle East, 2022 - 2032
• Figure 6-14: CRT Placement Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 6-15: CRT Placement Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 6-16: CRT Placement Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 6-17: CRT Placement Procedures by Country, Africa, 2022 - 2032
• Figure 6-18: Initial Placement CRT Procedures by Region, Global, 2022 - 2032
• Figure 6-19: Initial Placement CRT Procedures by Country, North America, 2022 - 2032
• Figure 6-20: Initial Placement CRT Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 6-21: Initial Placement CRT Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 6-22: Initial Placement CRT Procedures by Country, Western Europe, 2022 - 2032
• Figure 6-23: Initial Placement CRT Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 6-24: Initial Placement CRT Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 6-25: Initial Placement CRT Procedures by Country, Middle East, 2022 - 2032
• Figure 6-26: Initial Placement CRT Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 6-27: Initial Placement CRT Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 6-28: Initial Placement CRT Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 6-29: Initial Placement CRT Procedures by Country, Africa, 2022 - 2032
• Figure 6-30: Replacement CRT Procedures by Region, Global, 2022 - 2032
• Figure 6-31: Replacement CRT Procedures by Country, North America, 2022 - 2032
• Figure 6-32: Replacement CRT Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 6-33: Replacement CRT Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 6-34: Replacement CRT Procedures by Country, Western Europe, 2022 - 2032
• Figure 6-35: Replacement CRT Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 6-36: Replacement CRT Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 6-37: Replacement CRT Procedures by Country, Middle East, 2022 - 2032
• Figure 6-38: Replacement CRT Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 6-39: Replacement CRT Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 6-40: Replacement CRT Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 6-41: Replacement CRT Procedures by Country, Africa, 2022 - 2032
• Figure 6-42: CRT Device Market by Segment, Global, 2022 - 2032 (US$M)
• Figure 6-43: CRT Device Market by Region, Global, 2022 - 2032 (US$M)
• Figure 6-44: CRT Device Market, Global, 2022 - 2032
• Figure 6-45: Units Sold by Region, CRT Device Market, Global, 2022 - 2032
• Figure 6-46: Average Selling Price by Region, CRT Device Market, Global, 2022 - 2032 (US$)
• Figure 6-47: Market Value by Region, CRT Device Market, Global, 2022 - 2032 (US$M)
• Figure 6-48: CRT-P Market by Segment, Global, 2022 - 2032 (US$M)
• Figure 6-49: CRT-P Market, Global, 2022 - 2032
• Figure 6-50: Units Sold by Region, CRT-P Market, Global, 2022 - 2032
• Figure 6-51: Average Selling Price by Region, CRT-P Market, Global, 2022 - 2032 (US$)
• Figure 6-52: Market Value by Region, CRT-P Market, Global, 2022 - 2032 (US$M)
• Figure 6-53: Initial Placement CRT-P Market, Global, 2022 - 2032
• Figure 6-54: Units Sold by Region, Initial Placement CRT-P Market, Global, 2022 - 2032
• Figure 6-55: Average Selling Price by Region, Initial Placement CRT-P Market, Global, 2022 - 2032 (US$)
• Figure 6-56: Market Value by Region, Initial Placement CRT-P Market, Global, 2022 - 2032 (US$M)
• Figure 6-57: Replacement CRT-P Market, Global, 2022 - 2032
• Figure 6-58: Units Sold by Region, Replacement CRT-P Market, Global, 2022 - 2032
• Figure 6-59: Average Selling Price by Region, Replacement CRT-P Market, Global, 2022 - 2032 (US$)
• Figure 6-60: Market Value by Region, Replacement CRT-P Market, Global, 2022 - 2032 (US$M)
• 'Figure 6-61: CRT-D Market by Segment, Global, 2022 - 2032 (US$M)
• Figure 6-62: CRT-D Market, Global, 2022 - 2032
• Figure 6-63: Units Sold by Region, CRT-D Market, Global, 2022 - 2032
• Figure 6-64: Average Selling Price by Region, CRT-D Market, Global, 2022 - 2032 (US$)
• Figure 6-65: Market Value by Region, CRT-D Market, Global, 2022 - 2032 (US$M)
• Figure 6-66: Initial Placement CRT-D Market, Global, 2022 - 2032
• Figure 6-67: Units Sold by Region, Initial Placement CRT-D Market, Global, 2022 - 2032
• Figure 6-68: Average Selling Price by Region, Initial Placement CRT-D Market, Global, 2022 - 2032 (US$)
• Figure 6-69: Market Value by Region, Initial Placement CRT-D Market, Global, 2022 - 2032 (US$M)
• Figure 6-70: Replacement CRT-D Market, Global, 2022 - 2032
• Figure 6-71: Units Sold by Region, Replacement CRT-D Market, Global, 2022 - 2032
• Figure 6-72: Average Selling Price by Region, Replacement CRT-D Market, Global, 2022 - 2032 (US$)
• Figure 6-73: Market Value by Region, Replacement CRT-D Market, Global, 2022 - 2032 (US$M)
• Figure 6-74: Leading Competitors, CRT Market, Global, 2025
• Figure 6-75: Leading Competitors by Region, CRT Market, Global, 2025
• Figure 6-76: Leading Competitors by Region, CRT-D Market, Global, 2025
• Figure 6-77: Leading Competitors by Region, CRT-P Market, Global, 2025